• 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018. For more information

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

  • 22 April 2016

    EBOVAC1 has published their first report on Phase 1 data in the April 19th 2016 issue of JAMA

    Press release and more information

  • 04 April 2016

    The first subject was vaccinated on 30 March 2016 at the University of Nairobi, Kenya

  • 29 March 2016

    The 1st EBOVAC2 Newsletter is available!

  • 29 February 2016

    The first subject was randomized on 10 December 2016 at Makerere University in Uganda.

  • 29 February 2016

    The first subject was randomized at CHU Treichville in Côte d'Ivoire on 26 February 2016.

  • 11 February 2016

    The first subject was randomized at the Centre Muraz, Burkina Faso on the 11th of February 2016.

  • 11 February 2016

    EBOVAC2 and the 7 other IMI-funded Ebola+ attended the Cross-topic EbolA+ meeting organised by IMI on 2 February 2016.

  • 11 February 2016

    The EBOVAC1 & EBOVAC2 joint annual meetings were held in Paris on 20-22 January 2016.

  • 16 December 2015

    The first French subjects were randomized in France on 9 December 2015 at Cochin Hospital and on the 10 December at Henri Mondor Hospital in France.

  • 09 December 2015

    To find out more about Inserm's EBOVAC2 campaign to recruit volunteers for trials to test the vaccine against the Ebola virus (in French):


    Watch the video on Inserm's EBOVAC2 campaign (in French)

  • 09 December 2015

    Inserm is recruiting 300 volunteers to test the Ebola vaccine virus as part of Phase 2 trials. For more information, see the press release here

  • 09 November 2015

    The first volunteer was screened in France on 4 November 2015. More information coming soon.

  • 16 July 2015

    The University of Oxford has started enrolling volunteers into Phase 2 trials. For more information, click here.

  • 10 June 2015

    EBOVAC1 and EBOVAC2 presented a poster on both projects at Targeting Ebola in Paris, France, 28-29 May 2015.

    To view the poster, click here.

    Rodolphe Thiébaut, EBOVAC2 coordinator (Inserm), made a presentation on accelerated development of Ebola vaccines. More information.

  • 28 May 2015

    The EBOVAC2 website was launched! 

  • 28 May 2015

    The EBOVAC2 grant agreement between IMI2 and Inserm was signed on the 6th of March 2015.

  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research